Cyclacel Pharmaceuticals, Inc. Reports Fourth Quarter And Full Year 2013 Financial Results

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BERKELEY HEIGHTS, N.J., March 25, 2014 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company") announced today its financial results and business highlights for the fourth quarter and full year 2013. The Company's net loss applicable to common shareholders for the fourth quarter of 2013 was $3.6 million, or $0.19 per basic and diluted share, compared to a net loss applicable to common shareholders of $4.9 million, or $0.59 per basic and diluted share, for the fourth quarter of 2012. For the year ended December 31, 2013, the Company reported a net loss applicable to common shareholders of $19.5 million, or $1.28 per basic and diluted share, compared to a net loss applicable to common shareholders of $13.9 million or $1.68 per basic and diluted share, for the year ended December 31, 2012. As of December 31, 2013, cash and cash equivalents totaled $31.1 million.

Help employers find you! Check out all the jobs and post your resume.

Back to news